J&J and subsidiary pay $181M to settle landmark US case on improper marketing and advertising
This article was originally published in SRA
Executive Summary
Johnson & Johnson and its subsidiary Janssen Pharmaceuticals are paying $181 million to 36 states in the US and the District of Columbia to settle charges of improper marketing and promotion of the antipsychotics Risperdal (risperidone) and Invega (paliperidone), in the largest multi-state consumer protection-based pharmaceutical settlement in history1,2.